自願性公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 股份回購 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） – 1 – 本 公 司 將 繼 續 遵 守 適 用 於 股 份 回 購 的 相 關 規 則，並 會 及 時 履 行 其 披 露 責 任。 執行董事增持股份 執行董事陳飛先生已於2025年11月19日在公開市場購入合共200,000股 股 份。董 事 會 認 為，陳 先 生 增 持 股 份 顯 示 其 對 本 公 司 前 景 及 增 長 潛 力 充 滿 信 心，亦 展 示 其 對 本 公 司 的 長 期 承 諾。 本 公 司 的 股 份 回 購 計 劃 取 決 於 市 況，並 將 由 董 事 會 全 權 酌 情 決 定。對 於 實 施 股 份 回 購 計 劃 的 時 間、數 目 或 價 格，或 本 公 ...

Core Insights - The company announced a 15% year-on-year revenue growth for the three months ending September 30, 2025, surpassing the revenue growth rate of the first half of 2025 compared to the first half of 2024 [1] - The group's flagship business, including its proprietary brand operations, saw a transaction volume increase of over 120% year-on-year, with proprietary brand transactions growing over 350% in the same period [1] - The flagship business is a key strategic initiative under the "Upward Mobility" plan, significantly contributing to profitability [1] - The company is strategically expanding its proprietary brand product offerings to meet diverse market demands and drive continuous business growth [1]

Core Viewpoint - The company reported a 15% year-on-year increase in revenue for Q3 2025, driven by high-margin businesses such as its proprietary brands and primary push business, which saw transaction volumes grow by 120% and over 350% respectively in October [1][2]. Group 1: Company Performance - The rapid growth in performance is attributed to the company's "upward" strategy, focusing on enhancing supply chain capabilities and optimizing product structure [2]. - The proprietary brand business has significantly contributed to the company's profitability, with a notable increase in customer loyalty and repurchase rates due to high-quality, cost-effective products [2]. - The overall revenue growth in Q3 2025 is notably higher than the growth rate observed in the first half of 2025 compared to the first half of 2024, indicating strong performance despite industry challenges [1]. Group 2: Industry Context - The domestic pharmaceutical retail industry is undergoing a deep adjustment and transformation, facing challenges such as rising compliance costs and accelerated market clearing [1]. - The fourth quarter is traditionally a peak sales season for pharmaceuticals, with expectations that companies will exceed previous conservative performance forecasts due to increased flu activity compared to the previous year [3]. - The company's sales of flu-related medications increased by 36% year-on-year in October, with proprietary brand "Le Yaoshi" cold medications seeing a growth of over 135% [3].

Core Viewpoint - The company reported a 15% year-on-year increase in revenue for Q3 2025, driven by high-margin businesses such as its proprietary brands and first-push products, which saw transaction growth of 120% and over 350% respectively in October, enhancing customer loyalty and improving overall gross margin structure [1][2]. Group 1: Company Performance - The rapid growth in performance is attributed to the company's "upward" strategy, focusing on supply chain enhancement and product structure optimization, which includes strengthening strategic partnerships with upstream pharmaceutical companies and building a smart supply chain system [2]. - The proprietary brand business has shown significant growth, with sales scale increasing rapidly, contributing positively to the company's profitability and improving the overall gross margin structure [2][3]. - The company has maintained a double-digit revenue growth rate in a challenging domestic pharmaceutical retail environment, outperforming the growth rate from the first half of 2025 compared to the same period in 2024 [1]. Group 2: Industry Context - The pharmaceutical retail industry is currently undergoing a deep adjustment and transformation, facing challenges such as rising compliance costs and accelerated market clearing, impacting both upstream pharmaceutical companies and downstream retail pharmacies [1]. - The fourth quarter is traditionally a peak season for pharmaceutical sales, with expectations that companies' performance in Q3 and the second half of the year will exceed previous conservative forecasts, particularly due to a significant increase in flu activity compared to the previous year [3]. - The overall business growth and rapid development of high-value-added services validate the company's strategic shift from scale growth to quality growth, with upstream supply chain advantages and product differentiation becoming key to sustained performance [2].

Core Viewpoint - The company reported a revenue growth of over 15% year-on-year for the three months ending September 30, 2025, surpassing the revenue growth rate for the first half of 2025 compared to the first half of 2024 [1] Group 1: Financial Performance - The total transaction volume for the company's flagship brand promotion business increased by over 120% year-on-year in October 2025 [1] - The transaction volume for the company's own brand business saw a significant increase of over 350% during the same period [1] Group 2: Strategic Initiatives - The flagship brand promotion business is a key strategy in the company's "upward movement" plan and is crucial for enhancing profitability [1] - The company is strategically advancing the expansion of its own brand products, aiming to launch a diverse range of high-quality products that closely align with market demands [1]

Core Viewpoint - The company reported a revenue growth of over 15% year-on-year for the three months ending September 30, 2025, surpassing the revenue growth rate for the first half of 2025 compared to the first half of 2024 [1] Group 1: Financial Performance - The total transaction volume for the company's flagship brand promotion business, including its own brand business, increased by over 120% year-on-year in October 2025 [1] - The transaction volume for the company's own brand business saw a year-on-year increase of over 350% during the same period [1] Group 2: Strategic Initiatives - The flagship brand promotion business is a key strategy in the company's "upward movement" plan and is crucial for enhancing profitability [1] - The company is strategically advancing the expansion of its own brand products, aiming to launch a diverse range of high-quality products that closely align with market demands to meet the varied needs of downstream users [1]

Core Viewpoint - The company, Yaoshibang (09885.HK), reported a revenue growth of over 15% year-on-year for the three months ending September 30, 2025, surpassing the revenue growth rate for the first half of 2025 compared to the first half of 2024 [1] Group 1: Financial Performance - The total transaction volume for the company's flagship brand promotion business increased by over 120% year-on-year for the third quarter of 2025 [1] - The transaction volume for the company's own brand business saw a significant year-on-year increase of over 350% during the same period [1] Group 2: Strategic Initiatives - The flagship brand promotion business is a crucial part of the company's "upward movement" strategy and is essential for enhancing profitability [1] - The company is strategically advancing the expansion of its own brand products, aiming to launch a diverse range of high-quality products that closely align with market demands to meet the varied needs of downstream users [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 自願性公告 業務發展最新情況 本公告乃藥師幫股份有限公司（「本公司」）自 願 刊 發，以 告 知 其 股 東 及 潛 在 投 資 者有關本公司連同其附屬公司及綜合聯屬實體（「本集團」）若干業務發展最新 情 況。除 另 有 界 定 者 外，本 公 告 所 用 詞 彙 與 本 公 司 於2025年4月25日刊發的年度 報 告（「年 報」）所 界 定 者 具 相 同 涵 義。 茲提述本公司日期為2025年5月14日 及2025年10月9日有關業務發展最新情況的 自 願 性 公 告。董 事 會 欣 然 宣 佈，截 至2025年9月30日止三個月本集團收入同比 增長超過15%，超 過2025年上半年相較於2024年 上 半 年 的 ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 12, 2025, with China COSCO Shipping Holdings (01919) leading in terms of buyback amount and quantity. Group 1: Buyback Details - China COSCO Shipping Holdings (01919) repurchased 3 million shares for a total of 43.1382 million yuan, representing 0.770% of its total share capital [1][2] - Sinopec Limited (00386) repurchased 3.708 million shares for 16.5210 million yuan, accounting for 0.110% of its total share capital [2] - China International Marine Containers (02039) repurchased 2 million shares for 14.1189 million yuan, which is 1.090% of its total share capital [2] Group 2: Other Notable Buybacks - China Feihe Limited (06186) repurchased 2 million shares for 8.8511 million yuan, representing 1.074% of its total share capital [2] - AAC Technologies Holdings (02018) repurchased 221,500 shares for 8.8302 million yuan, which is 0.186% of its total share capital [2] - Linklogis Inc. (09959) repurchased 1,208,000 shares for 3.7894 million yuan, accounting for 4.685% of its total share capital [2] Group 3: Additional Companies - Mobi Development (00947) repurchased 50,000 shares for 8.0500 million yuan, which is 0.222% of its total share capital [3] - Tianfu (06868) repurchased 10,000 shares for 30,000 yuan, representing 0.051% of its total share capital [3] - Hylink Digital Solutions (01586) repurchased 80,000 shares for 22,100 yuan, accounting for 4.305% of its total share capital [3]

Group 1 - The latest shareholder equity disclosure for Hometown Interactive (03798) and Yaoshi Bang (09885) was conducted on November 13, 2025 [1] Group 2 - Hometown Interactive saw a reduction in shareholding from 67.8954 million shares to 58.2114 million shares, resulting in a current holding percentage of 4.54%, down from 5.29% previously [2] - The same reduction in shareholding was reported for Moomoo Trustee, Men Geng Network, and One One Eleven, all holding 4.54% after the change [2] - Yaoshi Bang's shareholder Chen Fei increased his holdings from 8.5 million shares to 8.6 million shares, with a current holding percentage of 1.26%, slightly up from 1.25% previously [2]